Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol by Kaya, Mehmet Gungor et al.
ORIGINAL ARTICLE
Cardiology Journal 
2014, Vol. 21, No. 4, pp. 434–441
DOI: 10.5603/CJ.a2013.0149
Copyright © 2014 Via Medica
ISSN 1897–5593
434 www.cardiologyjournal.org
Evaluation of beta-blockers on left ventricular 
dyssynchrony and reverse remodeling  
in idiopathic dilated cardiomyopathy:  
A randomized trial of carvedilol and metoprolol
Mehmet Gungor Kaya1, Bahadir Sarli1, Mahmut Akpek1, Esma Gunduz Kaya2,  
Mikail Yarlioglues1, Ramazan Topsakal1, Yat-Yin Lam3
1Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey 
2Department of Microbiology, Erciyes University School of Medicine, Kayseri, Turkey 
3Department of Medicine and Therapeutics, Prince of Wales Hospital,  
The Chinese University of Hong Kong, Hong Kong
Abstract
Background: The effect of b-blockage on cardiac dyssynchrony in idiopathic dilated cardio-
myopathy (IDC) is unknown. This study evaluated the impact of carvedilol and metoprolol 
succinate on left ventricular (LV) dyssynchrony and reverse remodeling in IDC.
Methods: In this small, prospective, double-blind study, we randomly assigned 81 IDC pa-
tients to receive carvedilol or metoprolol succinate. Echocardiographic measurements (dyssyn-
chrony, LV volumes and ejection fraction [EF]) and N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) levels were obtained at baseline and at first and sixth month of therapy.
Results: A total of 74 (91%) patients completed all investigations at sixth month (38 and 36 
taking carvedilol and metoprolol succinate, respectively). In the carvedilol group, reduction in 
LV end diastolic volume (D LVEDV at 6 months, 50 ± 15 mL to 40 ± 17 mL, p = 0.03) and 
increase in LVEF (D LVEF, 7 ± 2% to 5 ± 3%, p = 0.02) was higher compared to the meto-
prolol group. Also improvement in inter-ventricular dyssynchrony achieved with carvedilol was 
higher than metoprolol (D interventricular delay at 6 months, 11 ± 8 ms to 6 ± 7 ms, p = 0.03).  
However, improvement in intraventricular dyssynchrony was similar in the two groups  
(D intraventricular delay, 9 ± 7 ms to 9 ± 6 ms, p = 0.91). Improvements in LV mechanical 
dyssynchrony and reverse remodeling achieved with both drugs were accompanied by reduction 
in NT-proBNP levels in both carvedilol and metoprolol groups (1614 ± 685 pg/mL to 654 ± 
± 488 pg/mL and 1686 ± 730 pg/mL to 583 ± 396 pg/mL, respectively, p < 0.001 for both).
Conclusions: Although reduction in LVEDV and increase in LVEF was higher with carvedilol, 
improvement in intraventricular dyssynchrony was similar in carvedilol and metoprolol 
groups. (Cardiol J 2014; 21, 4: 434–441)
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Introduction
Heart failure (HF) is associated with marked 
morbidity, mortality and frequent hospitalizations 
in patients over 65 years of age. Treatment of HF 
in order to reduce its morbidity and mortality still 
remains one of the major challenges in health 
care practice. In approximately 30% of systolic 
HF patients, the disease affects the conduction 
system and leads to delayed electrical activation of 
the lateral part of the left ventricle (LV) [1]. Such 
intraventricular conduction delay, conventionally 
defined as electrocardiographic (ECG) QRS com-
plex duration > 120 ms, is known to be associated 
with adverse LV remodeling, clinical worsening and 
increased mortality [2]. Recent studies showed that 
various novel echocardiographic indices were more 
reliable than QRS duration in revealing underlying 
mechanical dyssynchrony and predicting clinical 
improvement after biventricular pacing [3].
Specific b-blockers such as carvedilol, meto-
prolol succinate, and bisoprolol decrease deaths 
and HF hospitalizations in patients with chronic 
systolic HF by reversing LV dilation and impro-
ving cardiac performance [4–7]. However, there 
are limited data on whether these b-blockers can 
influence cardiac mechanical dyssynchrony in 
patients with idiopathic dilated cardiomyopathy 
(IDC) [8]. In this study, we aimed to investigate 
the effect of carvedilol and metoprolol succinate 
on LV intra- and interventricular dyssynchrony and 
reverse remodeling in IDC patients.
Methods
Patient selection
Between August 2007 and June 2008, 104 con- 
secutive IDC patients were identified. How- 
 ever, only 81 patients fulfilled the inclusion criteria 
and were enrolled in the study. Inclusion criteria 
were: (1) LV ejection fraction (LVEF) < 40%, 
(2) chronic stable HF with New York Heart Associa- 
tion (NYHA) functional class II or III, (3) no sig-
nificant coronary artery stenosis confirmed by 
coronary angiography, (4) sinus rhythm, (5) no prior 
administration of b-blocker therapy, and (6) having 
mechanical intraventricular dyssynchrony as as-
sessed by echocardiography. Patients with prior 
history of coronary artery disease, cardiac surge-
ry, significant valvular heart disease, pacemaker 
implantation, and contra-indications to b-blockers 
were excluded. All patients received either maxi-
mal tolerated dose of ramipril with target dose of 
10 mg/d or candesartan with target dose of 16 mg/d 
in whom angiotensin-converting enzyme inhibitors 
(ACEI) was not tolerated. Adequate furosemide 
therapy was added if needed. All medications were 
optimized at least 6-months before enrollment and 
remained unchanged during the study period.
Eighty-one patients were consecutively ran-
domized in 1:1 ratio to receive carvedilol or me-
toprolol succinate. All patients signed an informed 
consent approved by our institutional review board 
and ethics committee. A total of 41 and 40 patients 
were assigned to receive carvedilol 3.125 mg twice 
daily and metoprolol succinate 25 mg once daily, 
respectively. The b-blocker dosage was titrated 
every 2 weeks to achieve target dose of 25 mg 
twice daily for carvedilol and 200 mg once daily for 
metoprolol succinate. Medication titration process 
was stopped if the patient experienced symptoma-
tic hypotension or bradycardia.
Echocardiography
All enrolled patients received echocardio-
graphy before and at first and sixth month after 
randomization. They were imaged in the left lateral 
decubitus position using the same ultrasound sy-
stem (VIVID 7, GE Vingmed Ultrasound, Horten, 
Norway) by 2 experienced cardiologists who were 
blinded to the clinical data. Two-dimensional and 
M-mode echocardiograms were obtained, accor-
ding to the American Society of Echocardiography 
guidelines. The LV volumes (end-systolic and 
end-diastolic: LVESV and LVEDV) and LVEF were 
calculated from conventional apical 2- and 4-cham-
ber images using biplane Simpson’s technique [9]. 
LV reverse remodeling was defined as a reduction 
of LVESV > 10% at 6-month follow-up.
Pulsed-wave tissue Doppler readings were 
measured from apical 4- and 5-chamber images. 
Gain and filter settings were adjusted to eliminate 
background noise for a clear tissue signal. The tis-
sue Doppler imaging (TDI) signals were recorded 
at a sweep speed of 100 mm/s. The sample volume 
was placed in the basal portions of the septal, poste-
rior and lateral walls of LV and that of right ventri-
cular (RV) free wall. The time interval between the 
onset of the QRS complex and the onset of the peak 
systolic velocity was derived at each region. Intra-
ventricular dyssynchrony was defined as the maxi-
mal time difference between 2 LV walls > 60 ms. 
Interventricular mechanical dyssynchrony referred 
to the maximal time difference between RV and 
LV walls > 56 ms [10]. All measurements were 
corrected for the heart rate (HR) using Bazett’s 
formula to avoid the confounding effect of HR 
changes during b-blocker therapy [11].
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Biochemical analysis
N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) levels were measured at baseline 
and 6-months. Blood samples were collected using 
antecubital venous puncture and transferred to 
EDTA-coated test tubes. Blood samples were then 
centrifuged in the hospital laboratory at 4°C and the 
plasma was frozen at –80°C. Plasma NT-proBNP 
level was determined immunoenzymatically using 
the NT-proBNP ELISA kit (Biomedica).
Reproducibility of the measurements
Intra- and inter-observer variabilities of echo-
cardiographic measurements were assessed in 
10 randomly chosen patients. Variability was 
calculated as the mean percent error, derived as 
the difference between 2 sets of measurements, 
divided by the mean of the observations. Both in-
vestigators were blinded to the patients’ diagnosis.
Statistical analysis
The Statistical Package for Social Sciences, 
version 13.0 (SPPS, Chicago, Illinois) was used 
for statistical analysis. Data were expressed as 
mean ± standard deviation for continuous variab-
les, and as numbers (percentages) for categorical 
variables. Continuous variables were analyzed 
by the unpaired Student’s t-test. Comparisons of 
pre- and post-treatment variables were made using 
the 2-tailed, paired Student’s t-test. Comparison 
of change in post-treatment and pre-treatment 
(∆ = [post-treatment value] – [pre-treatment 
value]) echocardiographic parameters and NT-
-proBNP between the two groups was performed 
using Student’s t-test. Pearson’s or Spearman’s 
correlation analysis was performed to estimate 
correlations between variables. A p value < 0.05 
was considered statistically significant.
Results
Only 74 (91%) patients (38 in carvedilol group 
and 36 in metoprolol group) completed the sche-
duled investigations. They all received maximal 
tolerated doses of either carvedilol or metoprolol 
succinate for up to 6 months after randomization, 
during which time the background therapy with an 
angiotensin II receptor blocker/ACEI and/or diure-
tic was continued. Seven of 81 patients did not com-
plete the study protocol (2 died, 1 developed sinus 
bradycardia and 4 were lost to follow-up, Fig. 1). 
The mean maintenance dose of b-blocker was 16 ± 
± 8 mg/day in carvedilol group and 57 ± 18 mg/day 
in metoprolol group.
Pre-treatment characteristics
Both groups had similar age, gender and 
other clinical characteristics (Table 1). Baseline 
LV volumes and EF, intra- and interventricular 
electromechanical delay measurements, and NT-
-proBNP values were similar between two groups.
Hemodynamic parameters
As expected, decrease in HR was noted at 
1 month in both groups (carvedilol: 81 ± 13 to 
75 ± 14 bpm; metoprolol: 79 ± 15 to 73 ± 11 bpm, 
p < 0.001 for both) with no further significant 
change at 6 months. When compared with baseli-
ne values change in HR at 6 months were similar 
in the two groups (D HR, 9 ± 12 to 9 ± 8 bpm, 
p = 0.91). Systolic blood pressure decreased 
from 118 ± 16 to 107 ± 15 mm Hg (p = 0.012) in 
carvedilol group and 114 ± 14 to 103 ± 13 mm Hg 
(p = 0.035) in metoprolol group at 6 months. The 
extent of decrease in systolic blood pressure was 
similar between the two groups. Diastolic blood 
pressure significantly decreased in carvedilol 
(76 ± 14 to 71 ± 9 mm Hg, p = 0.037) but not in 
metoprolol group (74 ± 12 to 70 ± 13 mm Hg, 
p = 0.42). Both groups had similar reductions in 
mean NYHA functional class values at the end of 
the study (Table 2).
LV reverse remodeling
Carvedilol or metoprolol succinate therapies 
improved LVEF, reduced LVEDV and LVESV 
after 1-month treatment. Improvement in LVEF 
continued up to 6 months in both carvedilol and 
metoprolol groups (31 ± 6 to 38 ± 6%, p < 0.001 
and 32 ± 4 to 37 ± 6%, p < 0.001, respectively). 
However, improvement in LVEF was higher in 
carvedilol group compared to metoprolol group 
Figure 1. Disposition of the patients.
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at the end of the sixth month (D LVEF, 7 ± 2% to 
5 ± 3%, p = 0.02, Table 3). In addition, both LVEDV 
and LVESV significantly decreased from baseline 
to 6 months in the two groups (Table 2). When 
compared with baseline values change in LVEDV 
at 6 months (D LVEDV, 50 ± 15 to 40 ± 17 mL, 
p = 0.03) was higher in carvedilol group but chan-
ge in LVESV (D LVESV, 25 ± 15 to 23 ± 9 mL, 
p = 0.28) was similar in the two groups (Table 3). 
LV reverse remodeling (LVESV decrease > 10%) 
was observed in 24 (63%) patients in carvedilol 
group and 25 (69%) patients in metoprolol group.
Intra- and interventricular dyssynchrony
During the 6-month follow-up intraventricular 
delay decreased from 67 ± 6 to 58 ± 10 ms (p < 0.001) 
in carvedilol group and 69 ± 7 to 60 ± 6 ms 
(p < 0.001) in metoprolol group (Table 2). Impro-
vement in intraventricular delay at 6 months was 
similar in the two groups (D intraventricular delay, 
9 ± 7 to 9 ± 6 ms, p = 0.91, Table 3). However, 
improvement in interventricular delay at 6 months 
was higher in carvedilol group (D interventricular 
delay, 11 ± 8 to 6 ± 7 ms, p = 0.03, Table 3). At the 
end of 6 months, there were no differences regar-
ding intra- and interventricular delay between the 
two groups (Fig. 2). Intra- and inter-observer varia-
bilities for intra- and interventricular dyssynchrony 
were 3.4%, 6.2% and 3.0%, 6.8%, respectively.
NT-proBNP levels
NT-proBNP values decreased significantly 
both in carvedilol (1614 ± 685 to 654 ± 488 pg/mL) 
and metoprolol (1686 ± 730 to 583 ± 396 pg/mL) 
groups at 6 months (p < 0.001 for both). However, 
decrease in plasma NT-proBNP level was similar in 
the two groups (D NT-proBNP, 960 ± 38 to 1103 ± 
± 470, p = 0.09). Also, the alteration in plasma 
NT-proBNP levels was positively correlated with 
a decreas in intraventricular dyssynchrony (Fig. 3).
Discussion
This study demonstrates that b-blockage 
with either carvedilol or metoprolol succinate in 
addition to standard medical therapy improves LV 
dyssynchrony, LVEF, LVESV and LVEDV. Decrease 
in NT-proBNP level accompanies improvement in 
LV function and dyssynchrony. Although carvedilol 
group showed higher decrease in LVEDV, and 
increase in LVEF, both drugs significantly improved 
LV dyssynchrony.
Approximately one third of the patients with 
HF demonstrate intraventricular conduction abnor-
malities [12]. Cardiac resynchronization therapy 
(CRT) improves symptoms and prolongs life in 
patients with refractory systolic HF and wide QRS 
complex (> 120 ms) on ECG [13]. In past years it 
was believed that wide QRS on ECG was the most 
Table 1. Baseline characteristics of patients with idiopathic dilated cardiomyopathy.
Carvedilol (n = 38) Metoprolol succinate (n = 36) P
Age [year] 58 ± 11 55 ± 12 0.74
Gender: male/female 21/17 22/14 0.64
Diabetes mellitus 11 (29%) 12   (33%) 0.68
NYHA functional class 2.3 ± 0.4 2.2 ± 0.4 0.81
Heart rate [bpm] 81 ± 13 79 ± 14 0.68
Systolic blood pressure [mm Hg] 118 ± 16 114 ± 14 0.38
Diastolic blood pressure [mm Hg] 76 ± 14 74 ± 12 0.64
QRS duration [ms] 126 ± 32 114 ± 23 0.48
Medications:
ACEI or ARB use 34 (90%) 33 (92%) 0.74
Diuretic use 28 (74%) 29 (81%) 0.48
Echocardiography:
LV end-diastolic volume [mL] 218 ± 52 204 ± 44 0.42
LV end-systolic volume [mL] 143 ± 40 133 ± 33 0.68
LV ejection fraction [%] 31 ± 6 32 ± 4 0.90
LV dyssynchrony [ms] 67 ± 5 69 ± 7 0.21
LV–RV dyssynchrony [ms] 53 ± 18 51 ± 17 0.64
NT-proBNP [pg/mL] 1614 ± 685 1686  ± 730 0.16
Results are presented as mean ± standard deviation; NYHA — New York Heart Association functional class; ACEI — angiotensin converting 
enzyme inhibitor; ARB — angiotensin receptor blocker; LV — left ventricular; LV dyssynchrony — intraventricular delay; LV–RV dyssynchrony 
— interventricular delay; NT-proBNP — N-terminal-pro-B-type natriuretic peptide
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Table 2. Comparison of the effects of carvedilol and metoprolol succinate over intra- and interventricu-
lar dyssynchronies, ventricular reverse remodeling and hemodynamics in the first and sixth months. 
Carvedilol (n = 38) Metoprolol succinate (n = 36) P
NYHA functional class:
   Baseline
   1st month
   6th month
2.3 ± 0.4
1.8 ± 0.5*
1.6 ± 0.5*
2.2 ± 0.4
1.8 ± 0.4*
1.7 ± 0.3*
0.81
0.73
0.42
Systolic blood pressure [mm Hg]
   Baseline
   1st month
   6th month
118 ± 16
113 ± 14
107 ± 15*
114 ± 14
109 ± 18*
103 ± 13*
0.38
0.57
0.74
Diastolic blood pressure [mm Hg]
   Baseline
   1st month
   6th month
76 ± 14
74 ± 10
71 ± 9*
74 ± 12
71 ± 15
70 ± 13
0.64
0.41
0.77
Heart rate [bpm]
   Baseline
   1st month
   6th month
81 ± 13
75 ± 14*
72 ± 10*
79 ± 14
73 ± 11*
70 ± 9*
0.68
0.77
0.92
LV ejection fraction [%]
   Baseline
   1st month
   6th month
31 ± 6
35 ± 7*
38 ± 6*#
32 ± 4
34 ± 5*
37 ± 6*#
0.90
0.79
0.52
LV end-diastolic volume [mL]
   Baseline
   1st month
   6th month
218 ± 51
183 ± 47*
168 ± 39*#
204 ± 44
180 ± 37*
164 ± 34*#
0.42
0.67
0.84
LV end-systolic volume [mL]
   Baseline
   1st month
   6th month
143 ± 36
131 ± 35*
118 ± 29*#
133 ± 33
117 ± 20*
110 ± 25*#
0.68
0.55
0.73
LV dyssynchrony [ms]
   Baseline
   1st month
   6th month
67 ± 6
62 ± 8*
58 ± 10*#
69 ± 7
64 ± 5
60 ± 6*
0.21
0.45
0.28
LV–RV dyssynchrony [ms]
   Baseline
   1st month
   6th month
53 ± 18
47 ± 16*
42 ± 15*#
51 ± 17
48 ± 14
45 ± 15*#
0.64
0.70
0.88
NT-proBNP [pg/L]
   Baseline
   1st month
   6th month
1614 ± 685
958  ± 621*
654 ± 488*#
1686 ± 730
1132 ± 776*
583 ± 396*#
0.16
0.32
0.43
Results are presented as mean ± standard deviation; abbreviations as in Table 1; *p < 0.05 between baseline and 1st month, 6th month;  
#p < 0.05 between 1st month and 6th month
Table 3. Change in selected variables during 6 months of treatment with either carvedilol or metoprolol 
succinate.
Carvedilol (n = 38) Metoprolol succinate (n = 36) P
D Ejection fraction [%] 7 ± 2 5 ± 3 0.02
D LV end-diastolic volume [mL] 50 ± 15 40 ± 17 0.03
D LV end-systolic volume [mL] 25 ± 15 23 ± 9 0.28
D Intraventricular delay [ms] 9 ± 7 9 ± 6 0.91
D Interventricular delay [ms] 11 ± 8 6 ± 7 0.03
D NT-proBNP level [pg/mL] 960 ± 38 1103 ± 470 0.09
Results are presented as mean ± standard deviation; D Change in selected variables during 6-month treatment; abbreviations as in Table 1
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Figure 3. Correlations between changes in plasma N-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels and 
left ventricular (LV) intraventricular dyssynchrony [ms] in carvedilol group (A) and in metoprolol group (B).
Figure 2. Representative graphics demonstrating the effects of beta-blocker therapy: Changes in N-terminal-pro-B-
-type natriuretic peptide (NT-proBNP) values (A), intraventricular delay (B), interventricular delay (C), and New York 
Heart Association (NYHA) classes (D).
powerful indicator of intraventricular dyssynchro-
ny. More recently, it has been pointed out that even 
patients with slightly prolonged or normal QRS 
may exhibit dyssynchrony [3].
In  mid 1990s, several studies showed that si-
multaneous electrical stimulation of both ventricles 
may improve cardiac function in HF patients with 
intrinsic conduction delay [14, 15]. In following 
years, CRT in addition to medical treatment was 
shown to improve dyssynchrony, induce LV reverse 
remodeling and reduce mortality in patients with 
systolic HF [16–18].
Beta-blockers were first introduced for HF tre-
atment in 1975 by Waagstein [19]. Contemporary 
HF treatment guidelines recommend addition of 
carvedilol, metoprolol XL or bisoprolol to conven-
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tional therapy for treatment of systolic HF, based 
on the results of randomized studies [4–6, 20, 
21]. Carvedilol and metoprolol succinate are the 
most widely used b-blockers in HF management 
worldwide. Carvedilol functions by blocking b1-, 
b2-, and a1-adrenoreceptor, whereas metoprolol 
blockes b1 adrenoreceptors [22]. Although isolated 
studies demonstrated a reduction in mechanical 
dyssynchrony with carvedilol in systolic HF pa-
tients [8, 23], there is a lack of data comparing its 
therapeutic effects on mechanical dyssynchrony 
with metoprolol in IDC patients.
Progressive ventricular dilatation existing 
in patients with IDC usually accompanies intra-
ventricular dyssynchrony. Optimal medical treat-
ment with b-blockers have been shown to induce 
reverse remodeling which may eventually lead 
to improvement in LV mechanical dyssynchrony 
[24]. The mechanism of these benefits is likely 
multifactorial and related to negative chronotropy, 
which reduces myocardial oxygen consumption, 
reduction of the impact of high intramyocardial 
norepinephrine levels [25]. In reversing LV dila-
tation b-blockers appear to be superior to the 
other classes of drugs, with a stronger correla-
tion between dose and effect [26, 27]. Several 
trials have been conducted to find out the most 
efficient b-blocker in improving LV function and 
reducing LVEDV and LVESV [28]. Ruwald et al. 
[29] reported less HF hospitalizations or deaths 
in systolic HF patients taking carvedilol than me-
toprolol, in particular patients with CRT and left 
bundle branch block, implying a novel, synergistic 
effect with carvedilol. However, a meta-analysis 
written by Chatterjee et al. [30] suggested that 
the benefits of b-blockers in systolic HF seem to 
be mainly due to a class effect, as no statistical 
evidence from current trials supports the supe-
riority of any single agent over the others.
In our study, although decrease in LVEDV 
achieved with carvedilol was higher than in the 
metoprolol group, both drugs led to reverse remo-
deling and improvement in LV dyssynchrony achie-
ved with these two drugs were similar. We consider 
that a longer follow up period may be needed to 
observe the beneficial effects of LV reverse remo-
deling on intraventricular dyssynchrony. However, 
carvedilol was superior to metoprolol in restoring 
interventricular dyssynchrony in our study. Our 
results clearly confirm the beneficial effects of 
either b-blocker on mechanical dyssynchrony at 
6-month follow-up. However, none of these drugs 
were superior to another in improving intraven-
tricular dyssynchrony. The mechanisms involved 
in the LV resynchronization with carvedilol or 
metoprolol succinate are not clearly elucidated. 
Although carvedilol and metoprolol succinate have 
different mechanisms of action on b-receptors, the 
induction of LV reverse remodeling obtained with 
both drugs may play a role in the improvement of 
LV dyssynchrony.
Limitations of the study
Most of the limitations are inherent to the 
relatively small sample size and modest follow-up 
period. Other more advanced echocardiographic 
techniques like speckle-tracking may be more 
robust than pulsed-wave TDI in assessing mecha-
nical dyssynchrony. In addition, this study did not 
use cardiac magnetic resonance to rule out other 
causes of HF. Lastly, the addition of a placebo group 
would be helpful in interpreting the results more 
accurately.
Conclusions
Both carvedilol and metoprolol improved 
intraventricular dyssynchrony and induced LV re-
verse remodeling at 6 months in patients with IDC. 
The extent of reverse remodeling and reduction 
in interventricular dyssynchrony achieved with 
carvedilol was, however, significantly increased 
when compared to metoprolol.
Conflict of interest: none declared
References 
 1.  Farwell D, Patel NR, Hall A et al. How many people with heart 
failure are appropriate for biventricular resynchronization? Eur 
Heart J, 2000; 21: 1246–1250.
 2.  Cazeau S, Leclercq C, Lavergne T et al. Multisite Stimulation 
in Cardiomyopathies (MUSTIC) Study Investigators. Effects of 
multisite biventricular pacing in patients with heart failure and 
intraventricular conduction delay. N Engl J Med, 2001; 344: 
873–880.
 3.  Yu CM, Lin H, Zhang Q et al. High prevalence of left ventricular 
systolic and diastolic dyssynchrony in patients with congestive 
heart failure and normal QRS duration. Heart, 2003; 89: 54–60.
 4.  MERIT-HF Study Group. Effect of metoprolol succinate CR/XL 
in chronic heart failure: Metoprolol succinate CR/XL Randomi-
sed Intervention Trial in Congestive Heart Failure (MERIT-HF). 
Lancet, 1999; 353: 2001–2007.
 5.  Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of 
carvedilol and metoprolol on clinical outcomes in patients with 
chronic heart failure in the Carvedilol or Metoprolol European 
Trial. Lancet, 2003; 362: 7–13.
 6.  CIBIS-II Investigators and Committees. The Cardiac Insufficien-
cy Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet, 
1999; 353: 9–13.
 7.  Kamei M, Morita S, Hayashi Y et al. Carvedilol versus Metopro-
lol for the prevention of atrial fibrillation after off-pump coronary 
bypass surgery: Rationale and design of the Carvedilol or Meto-
www.cardiologyjournal.org 441
Mehmet Gungor Kaya et al., A randomized trial of carvedilol vs. metoprolol on LV dyssynchrony
prolol Post-Revascularization Atrial Fibrillation Controlled Trial 
(COMPACT). Cardiovasc Drugs Ther, 2006; 20: 219–227.
 8.  Takemoto Y, Hozumi T, Sugioka K et al. Beta-blocker therapy 
induces ventricular resynchronization in dilated cardiomyopathy 
with narrow QRS. J Am Coll Cardiol, 2007; 49: 778–783.
 9.  Schiller NB, Shah PM, Crawford M et al. Recommendations for 
quantitation of the left ventricle by two-dimensional echocardio-
graphy. American Society of Echocardiography Committee on 
Standards, Subcommittee on Quantitation of Two-Dimensional 
Echocardiograms. J Am Soc Echocardiogr, 1989; 2: 358–367.
 10.  Penicka M, Bartunek J, De Bruyne B et al. Improvement of left 
ventricular function after cardiac resynchronization therapy is 
predicted by tissue Doppler imaging echocardiography. Circula-
tion, 2004; 109: 978–983.
 11.  Bazett HC. An analysis of the time-relations of the electrocardia-
gram. Heart, 1920; 7: 353–370.
 12.  Ghio S, Constantin C, Klersy C et al. Interventricular and intra-
ventricular dyssynchrony are common in heart failure patients, 
regardless of QRS duration. Eur Heart J, 2004; 25: 571–578.
 13.  Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchro-
nization in chronic heart failure. N Engl J Med, 2002; 346: 
1845–1853.
 14.  Foster AH, Gold MR, McLaughlin JS. Acute hemodynamic effects 
of atrio-biventricular pacing in humans. Ann Thorac Surg, 1995; 
59: 294–300.
 15.  Kass DA, Chen CH, Curry C et al. Improved left ventricular 
mechanics from acute VDD pacing in patients with dilated car-
diomyopathy and ventricular conduction delay. Circulation, 1999; 
99: 1567–1573.
 16.  Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchroniza-
tion therapy with or without an implantable defibrillator in advan-
ced chronic heart failure. N Engl J Med, 2004; 350: 2140–2150.
 17.  Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac 
resynchronization on morbidity and mortality in heart failure. 
N Engl J Med, 2005; 352: 1539–1549.
 18.  Vatankulu MA, Goktekin O, Kaya MG et al. Effect of long-term 
resynchronization therapy on left ventricular remodeling in pace-
maker patients upgraded to biventricular devices. Am J Cardiol, 
2009; 103: 1280–1284.
 19.  Waagstein F, Hjalmarson Å, Varnaukas E et al. Effect of chronic 
beta-adrenergic receptor blockade in congestive cardiomyopathy. 
Br Heart J, 1975; 37: 1022–1036.
 20.  Dobre D, van Veldhuisen DJ, Mordenti G et al. Tolerability and 
dose-related effects of nebivolol in elderly patients with heart fai-
lure: Data from the Study of the Effects of Nebivolol Intervention 
on Outcomes and Rehospitalisation in Seniors with Heart Failure 
(SENIORS) trial. Am Heart J, 2007; 154: 109–115.
 21.  Udelson JE. Ventricular remodeling in heart failure and the effect 
of beta-blockade. Am J Cardiol, 2004; 93: 43B–48B.
 22.  Beattie K, Phadke G, Novakovic J. Carvedilol. Profiles Drug 
Subst Excip Relat Methodol, 2013; 38: 113–157.
 23.  Castro PF, Mc-Nab P, Quintana JC et al. Effects of carvedilol upon 
intra- and interventricular synchrony in patients with chronic 
heart failure. Am J Cardiol, 2005; 96: 267–269.
 24.  Doughty RN, Whalley GA, Walsh H et al. Effects of carvedilol 
on left ventricular remodeling after acute myocardial infarction: 
The CAPRICORN ECHO study. Circulation, 2004; 109: 201– 
–206.
 25.  Eapen Z, Rogers JG. Strategies to attenuate pathological remode-
ling in heart failure. Curr Opin Cardiol, 2009; 24: 223–229.
 26.  Frigerio M, Roubina E. Drugs for left ventricular remodeling in 
heart failure. Am J Cardiol, 2005; 96 (12A): 10L–18L.
 27.  Sarli B, Topsakal R, Kaya EG et al. Tenascin-C as predictor of 
left ventricular remodeling and mortality in patients with dilated 
cardiomyopathy. J Investig Med, 2013; 61: 728–732.
 28.  Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of 
carvedilol and metoprolol on clinical outcomes in patients with 
chronic heart failure in the Carvedilol Or Metoprolol European 
Trial (COMET): Randomised controlled trial. Lancet, 2003; 362: 
7–13.
 29.  Ruwald MH, Ruwald AC, Jons C et al. Effect of metoprolol versus 
carvedilol on outcomes in MADIT-CRT (multicenter automatic 
defibrillator implantation trial with cardiac resynchronization 
therapy). J Am Coll Cardiol, 2013; 61: 1518–1526.
 30.  Chatterjee S, Biondi-Zoccai G, Abbate A et al. Benefits of beta-
-blockers in patients with heart failure and reduced ejection 
fraction: Network meta-analysis. BMJ, 2013; 346: doi: 10.1136/ 
/bmj.f55.
